Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature

Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib

(2018) Asher M. Marks et al.   PEDIATRIC BLOOD & CANCER

Targeted therapy for infants with diencephalic syndrome: A case report and review of management strategies

(2018) Lars M. Wagner et al.   PEDIATRIC BLOOD & CANCER

Rathke's Cleft Cyst as Origin of a Pediatric Papillary Craniopharyngioma

(2018) Sven-Martin Schlaffer et al.   Frontiers in Genetics

A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study

(2017) Anuradha Banerjee et al.   NEURO-ONCOLOGY

Proton Beam Therapy for Pediatric Brain Tumor

(2017) Masashi MIZUMOTO et al.   NEUROLOGIA MEDICO-CHIRURGICA

Papillary craniopharyngioma: A clinicopathologic study of a rare entity from a major tertiary care center in Pakistan

(2017) NasirUd Din et al.   NEUROLOGY INDIA

Dramatic clinical and radiographic response to BRAF inhibition in a patient with progressive disseminated optic pathway glioma refractory to MEK inhibition

(2017) Abhishek Bavle et al.   PEDIATRIC HEMATOLOGY AND ONCOLOGY

Analysis and Long-Term Follow-Up of the Surgical Treatment of Children With Craniopharyngioma

(2016) Jing Cheng et al.   JOURNAL OF CRANIOFACIAL SURGERY

Profound clinical and radiological response to BRAF inhibition in a 2-month-old diencephalic child with hypothalamic/chiasmatic glioma

(2016) Alvaro Lassaletta et al.   PEDIATRIC BLOOD & CANCER

Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles

(2016) Annett Hölsken et al.   Acta Neuropathologica Communications

BRAF V600E mutation is a useful marker for differentiating Rathke’s cleft cyst with squamous metaplasia from papillary craniopharyngioma

(2015) Jang-Hee Kim et al.   JOURNAL OF NEURO-ONCOLOGY

Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy

(2015) Priscilla K. Brastianos et al.   JNCI-Journal of the National Cancer Institute

BRAF V600Eanalysis for the differentiation of papillary craniopharyngiomas and Rathke's cleft cysts

(2015) Leonille Schweizer et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Successful Retreatment of a Child with a Refractory Brainstem Ganglioglioma with Vemurafenib

(2015) Dolly Aguilera et al.   PEDIATRIC BLOOD & CANCER

Targeted BRAF and CTNNB1 next-generation sequencing allows proper classification of nonadenomatous lesions of the sellar region in samples with limiting amounts of lesional cells

(2015) Gianluca Marucci et al.   Pituitary

Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor

(2015) Simon J. B. Aylwin et al.   Pituitary

Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy

(2015) Priscilla K. Brastianos et al.   JNCI-Journal of the National Cancer Institute

Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas

(2014) Priscilla K Brastianos et al.   NATURE GENETICS

Markers of Recurrence and Long-Term Morbidity in Craniopharyngioma: A Systematic Analysis of 171 Patients

(2012) Alain Gautier et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Childhood craniopharyngioma

(2012) Hermann L. Müller   Pituitary

Clinicopathological Characteristics of Adamantinomatous and Papillary Craniopharyngiomas: University of California, San Francisco Experience 1985–2005

(2010) Melike Pekmezci et al.   NEUROSURGERY

Radiation therapy for pediatric craniopharyngioma

(2010) Erin N. Kiehna et al.   Neurosurgical Focus